ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Nonsteroidal MRAs Improve Heart Failure Outcomes. 10/24/25"
Episode Synopsis
Welcome to Cardiology Today – Recorded October 24, 2025. This episode summarizes 5 key cardiology studies on topics like genetic diagnosis and mineralocorticoid receptor antagonists. Key takeaway: Nonsteroidal MRAs Improve Heart Failure Outcomes..
Article Links:
Article 1: P-Wave Indices and the Risks of Incident Atrial Fibrillation and Ischemic Stroke in Black Adults: The Jackson Heart Study. (Journal of the American Heart Association)
Article 2: Clinically Actionable Hypertrophic Cardiomyopathy Genes in South Asian Indian Patients. (Journal of the American Heart Association)
Article 3: Utility of High-Sensitivity Cardiac Troponin-T and N-Terminal Pro-B-Type Natriuretic Peptide to Predict Survival, Quality of Life, and Functional Status Changes After Transcatheter Aortic Valve Implantation. (Journal of the American Heart Association)
Article 4: Nonsteroidal Versus Steroidal Mineralocorticoid Receptor Antagonists in Heart Failure: Real-World Evidence From a Multicenter Cohort Study. (Journal of the American Heart Association)
Article 5: Rivaroxaban in Peripheral Artery Disease After Revascularization: Worst Events and Net Outcomes in VOYAGER PAD. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/nonsteroidal-mras-improve-heart-failure-outcomes-10-24-25/
Featured Articles
Article 1: P-Wave Indices and the Risks of Incident Atrial Fibrillation and Ischemic Stroke in Black Adults: The Jackson Heart Study.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41133805
Summary: This prospective cohort study, involving 4900 Black adults without atrial fibrillation at baseline, investigated the relationship between electrocardiographic P-wave indices, as measures of atrial cardiomyopathy, and incident atrial fibrillation and ischemic stroke. The study found that specific P-wave indices were significantly associated with an increased risk of both developing atrial fibrillation and experiencing an ischemic stroke within this population. These findings highlight P-wave indices as valuable early prognostic markers, offering a new approach for risk stratification in Black adults who face a disproportionate burden of atrial fibrillation-related complications. This research establishes the clinical utility of these markers to guide targeted interventions and improve outcomes.
Article 2: Clinically Actionable Hypertrophic Cardiomyopathy Genes in South Asian Indian Patients.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41128141
Summary: This study aimed to identify the prevalence of clinically actionable gene variants for primary hypertrophic cardiomyopathy in South Asian Indian patients, addressing existing data gaps and disparities in ancestry-specific variant interpretation. The research successfully identified distinct clinically actionable hypertrophic cardiomyopathy gene variants within this specific population, using established guidelines like the ClinGen Hereditary Cardiovascular Disorders Gene Curation Expert Panel. These findings provide crucial genetic insights, enhancing the understanding of hypertrophic cardiomyopathy’s etiology in South Asian Indian individuals. This work is essential for improving accurate genetic diagnosis, facilitating robust risk stratification, and enabling effective cascade screening within affected South Asian Indian families, ultimately minimizing interpretation disparities and improving patient care.
Article 3: Utility of High-Sensitivity Cardiac Troponin-T and N-Terminal Pro-B-Type Natriuretic Peptide to Predict Survival, Quality of Life, and Functional Status Changes After Transcatheter Aortic Valve Implantation.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41128137
Summary: This prospective observational cohort study, involving 173 patients, evaluated the prognostic utility of pre-transcatheter aortic valve implantation N-terminal pro-B-type natriuretic peptide and high-sensitivity cardiac troponin T levels. The study discovered that elevated pre-procedural levels of both N-terminal pro-B-type natriuretic peptide and high-sensitivity cardiac troponin T were significant predictors of poorer survival, reduced quality of life, and diminished functional status changes after transcatheter aortic valve implantation. These findings demonstrate that these cardiac biomarkers offer substantial prognostic value beyond current clinical assessments. Consequently, these biomarkers can be incorporated into aortic valve guidelines to enhance risk stratification and guide more informed patient selection for transcatheter aortic valve implantation.
Article 4: Nonsteroidal Versus Steroidal Mineralocorticoid Receptor Antagonists in Heart Failure: Real-World Evidence From a Multicenter Cohort Study.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41128135
Summary: This retrospective, propensity score-matched cohort study utilized the TriNetX database to provide real-world evidence comparing nonsteroidal and steroidal mineralocorticoid receptor antagonists in heart failure patients. The study enrolled adult patients diagnosed with heart failure who initiated either type of mineralocorticoid receptor antagonist between January 2021 and February 2025. The research demonstrated that nonsteroidal mineralocorticoid receptor antagonists, exemplified by finerenone, offer comparable or superior clinical benefits in reducing mortality and hospitalization rates in heart failure patients. This evidence expands therapeutic options for heart failure management, supporting the selection of mineralocorticoid receptor antagonists to improve patient outcomes in a real-world setting.
Article 5: Rivaroxaban in Peripheral Artery Disease After Revascularization: Worst Events and Net Outcomes in VOYAGER PAD.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41128134
Summary: This analysis of the VOYAGER P.A.D. trial data evaluated the efficacy and safety of rivaroxaban 2.5 milligrams twice daily in patients with peripheral artery disease after revascularization, specifically focusing on “worst events” and net clinical outcomes. The study affirmed rivaroxaban’s benefit in reducing major thrombotic vascular events, building upon the initial finding of a reduced first event in a composite endpoint. It further clarified rivaroxaban’s impact on a spectrum of adverse events, demonstrating an improved overall patient safety and efficacy profile. This comprehensive assessment solidifies rivaroxaban’s role as a vital adjunct to antiplatelet therapy, substantially improving long-term outcomes and reducing re-interventions for peripheral artery disease patients post-revascularization.
Transcript
Today’s date is October 24, 2025. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. P-Wave Indices and the Risks of Incident Atrial Fibrillation and Ischemic Stroke in Black Adults: The Jackson Heart Study. This prospective cohort study, involving 4900 Black adults without atrial fibrillation at baseline, investigated the relationship between electrocardiographic P-wave indices, as measures of atrial cardiomyopathy, and incident atrial fibrillation and ischemic stroke. The study found that specific P-wave indices were significantly associated with an increased risk of both developing atrial fibrillation and experiencing an ischemic stroke within this population. These findings highlight P-wave indices as valuable early prognostic markers, offering a new approach for risk stratification in Black adults who face a disproportionate burden of atrial fibrillation-related complications. This research establishes the clinical utility of these markers to guide targeted interventions and improve outcomes.
Article number two. Clinically Actionable Hypertrophic Cardiomyopathy Genes in South Asian Indian Patients. This study aimed to identify the prevalence of clinically actionable gene variants for primary hypertrophic cardiomyopathy in South Asian Indian patients, addressing existing data gaps and disparities in ancestry-specific variant interpretation. The research successfully identified distinct clinically actionable hypertrophic cardiomyopathy gene variants within this specific population, using established guidelines like the ClinGen Hereditary Cardiovascular Disorders Gene Curation Expert Panel. These findings provide crucial genetic insights, enhancing the understanding of hypertrophic cardiomyopathy’s etiology in South Asian Indian individuals. This work is essential for improving accurate genetic diagnosis, facilitating robust risk stratification, and enabling effective cascade screening within affected South Asian Indian families, ultimately minimizing interpretation disparities and improving patient care.
Article number three. Utility of High-Sensitivity Cardiac Troponin-T and N-Terminal Pro-B-Type Natriuretic Peptide to Predict Survival, Quality of Life, and Functional Status Changes After Transcatheter Aortic Valve Implantation. This prospective observational cohort study, involving 173 patients, evaluated the prognostic utility of pre-transcatheter aortic valve implantation N-terminal pro-B-type natriuretic peptide and high-sensitivity cardiac troponin T levels. The study discovered that elevated pre-procedural levels of both N-terminal pro-B-type natriuretic peptide and high-sensitivity cardiac troponin T were significant predictors of poorer survival, reduced quality of life, and diminished functional status changes after transcatheter aortic valve implantation. These findings demonstrate that these cardiac biomarkers offer substantial prognostic value beyond current clinical assessments. Consequently, these biomarkers can be incorporated into aortic valve guidelines to enhance risk stratification and guide more informed patient selection for transcatheter aortic valve implantation.
Article number four. Nonsteroidal Versus Steroidal Mineralocorticoid Receptor Antagonists in Heart Failure: Real-World Evidence From a Multicenter Cohort Study. This retrospective, propensity score-matched cohort study utilized the TriNetX database to provide real-world evidence comparing nonsteroidal and steroidal mineralocorticoid receptor antagonists in heart failure patients. The study enrolled adult patients diagnosed with heart failure who initiated either type of mineralocorticoid receptor antagonist between January 2021 and February 2025. The research demonstrated that nonsteroidal mineralocorticoid receptor antagonists, exemplified by finerenone, offer comparable or superior clinical benefits in reducing mortality and hospitalization rates in heart failure patients. This evidence expands therapeutic options for heart failure management, supporting the selection of mineralocorticoid receptor antagonists to improve patient outcomes in a real-world setting.
Article number five. Rivaroxaban in Peripheral Artery Disease After Revascularization: Worst Events and Net Outcomes in VOYAGER PAD. This analysis of the VOYAGER P.A.D. trial data evaluated the efficacy and safety of rivaroxaban 2.5 milligrams twice daily in patients with peripheral artery disease after revascularization, specifically focusing on “worst events” and net clinical outcomes. The study affirmed rivaroxaban’s benefit in reducing major thrombotic vascular events, building upon the initial finding of a reduced first event in a composite endpoint. It further clarified rivaroxaban’s impact on a spectrum of adverse events, demonstrating an improved overall patient safety and efficacy profile. This comprehensive assessment solidifies rivaroxaban’s role as a vital adjunct to antiplatelet therapy, substantially improving long-term outcomes and reducing re-interventions for peripheral artery disease patients post-revascularization.
Thank you for listening. Don’t forget to subscribe.
Keywords
genetic diagnosis, mineralocorticoid receptor antagonists, hospitalization, N-terminal pro-B-type natriuretic peptide, hypertrophic cardiomyopathy, ischemic stroke, South Asian Indian, Black adults, rivaroxaban, atrial fibrillation, heart failure, ClinGen, genetic variants, thrombotic events, mortality, antiplatelet therapy, high-sensitivity cardiac troponin T, quality of life, revascularization, peripheral artery disease, P-wave indices, atrial cardiomyopathy, finerenone, transcatheter aortic valve implantation.
About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • FollowThe post Nonsteroidal MRAs Improve Heart Failure Outcomes. 10/24/25 first appeared on Cardiology Today.
Article Links:
Article 1: P-Wave Indices and the Risks of Incident Atrial Fibrillation and Ischemic Stroke in Black Adults: The Jackson Heart Study. (Journal of the American Heart Association)
Article 2: Clinically Actionable Hypertrophic Cardiomyopathy Genes in South Asian Indian Patients. (Journal of the American Heart Association)
Article 3: Utility of High-Sensitivity Cardiac Troponin-T and N-Terminal Pro-B-Type Natriuretic Peptide to Predict Survival, Quality of Life, and Functional Status Changes After Transcatheter Aortic Valve Implantation. (Journal of the American Heart Association)
Article 4: Nonsteroidal Versus Steroidal Mineralocorticoid Receptor Antagonists in Heart Failure: Real-World Evidence From a Multicenter Cohort Study. (Journal of the American Heart Association)
Article 5: Rivaroxaban in Peripheral Artery Disease After Revascularization: Worst Events and Net Outcomes in VOYAGER PAD. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/nonsteroidal-mras-improve-heart-failure-outcomes-10-24-25/
Featured Articles
Article 1: P-Wave Indices and the Risks of Incident Atrial Fibrillation and Ischemic Stroke in Black Adults: The Jackson Heart Study.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41133805
Summary: This prospective cohort study, involving 4900 Black adults without atrial fibrillation at baseline, investigated the relationship between electrocardiographic P-wave indices, as measures of atrial cardiomyopathy, and incident atrial fibrillation and ischemic stroke. The study found that specific P-wave indices were significantly associated with an increased risk of both developing atrial fibrillation and experiencing an ischemic stroke within this population. These findings highlight P-wave indices as valuable early prognostic markers, offering a new approach for risk stratification in Black adults who face a disproportionate burden of atrial fibrillation-related complications. This research establishes the clinical utility of these markers to guide targeted interventions and improve outcomes.
Article 2: Clinically Actionable Hypertrophic Cardiomyopathy Genes in South Asian Indian Patients.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41128141
Summary: This study aimed to identify the prevalence of clinically actionable gene variants for primary hypertrophic cardiomyopathy in South Asian Indian patients, addressing existing data gaps and disparities in ancestry-specific variant interpretation. The research successfully identified distinct clinically actionable hypertrophic cardiomyopathy gene variants within this specific population, using established guidelines like the ClinGen Hereditary Cardiovascular Disorders Gene Curation Expert Panel. These findings provide crucial genetic insights, enhancing the understanding of hypertrophic cardiomyopathy’s etiology in South Asian Indian individuals. This work is essential for improving accurate genetic diagnosis, facilitating robust risk stratification, and enabling effective cascade screening within affected South Asian Indian families, ultimately minimizing interpretation disparities and improving patient care.
Article 3: Utility of High-Sensitivity Cardiac Troponin-T and N-Terminal Pro-B-Type Natriuretic Peptide to Predict Survival, Quality of Life, and Functional Status Changes After Transcatheter Aortic Valve Implantation.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41128137
Summary: This prospective observational cohort study, involving 173 patients, evaluated the prognostic utility of pre-transcatheter aortic valve implantation N-terminal pro-B-type natriuretic peptide and high-sensitivity cardiac troponin T levels. The study discovered that elevated pre-procedural levels of both N-terminal pro-B-type natriuretic peptide and high-sensitivity cardiac troponin T were significant predictors of poorer survival, reduced quality of life, and diminished functional status changes after transcatheter aortic valve implantation. These findings demonstrate that these cardiac biomarkers offer substantial prognostic value beyond current clinical assessments. Consequently, these biomarkers can be incorporated into aortic valve guidelines to enhance risk stratification and guide more informed patient selection for transcatheter aortic valve implantation.
Article 4: Nonsteroidal Versus Steroidal Mineralocorticoid Receptor Antagonists in Heart Failure: Real-World Evidence From a Multicenter Cohort Study.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41128135
Summary: This retrospective, propensity score-matched cohort study utilized the TriNetX database to provide real-world evidence comparing nonsteroidal and steroidal mineralocorticoid receptor antagonists in heart failure patients. The study enrolled adult patients diagnosed with heart failure who initiated either type of mineralocorticoid receptor antagonist between January 2021 and February 2025. The research demonstrated that nonsteroidal mineralocorticoid receptor antagonists, exemplified by finerenone, offer comparable or superior clinical benefits in reducing mortality and hospitalization rates in heart failure patients. This evidence expands therapeutic options for heart failure management, supporting the selection of mineralocorticoid receptor antagonists to improve patient outcomes in a real-world setting.
Article 5: Rivaroxaban in Peripheral Artery Disease After Revascularization: Worst Events and Net Outcomes in VOYAGER PAD.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41128134
Summary: This analysis of the VOYAGER P.A.D. trial data evaluated the efficacy and safety of rivaroxaban 2.5 milligrams twice daily in patients with peripheral artery disease after revascularization, specifically focusing on “worst events” and net clinical outcomes. The study affirmed rivaroxaban’s benefit in reducing major thrombotic vascular events, building upon the initial finding of a reduced first event in a composite endpoint. It further clarified rivaroxaban’s impact on a spectrum of adverse events, demonstrating an improved overall patient safety and efficacy profile. This comprehensive assessment solidifies rivaroxaban’s role as a vital adjunct to antiplatelet therapy, substantially improving long-term outcomes and reducing re-interventions for peripheral artery disease patients post-revascularization.
Transcript
Today’s date is October 24, 2025. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. P-Wave Indices and the Risks of Incident Atrial Fibrillation and Ischemic Stroke in Black Adults: The Jackson Heart Study. This prospective cohort study, involving 4900 Black adults without atrial fibrillation at baseline, investigated the relationship between electrocardiographic P-wave indices, as measures of atrial cardiomyopathy, and incident atrial fibrillation and ischemic stroke. The study found that specific P-wave indices were significantly associated with an increased risk of both developing atrial fibrillation and experiencing an ischemic stroke within this population. These findings highlight P-wave indices as valuable early prognostic markers, offering a new approach for risk stratification in Black adults who face a disproportionate burden of atrial fibrillation-related complications. This research establishes the clinical utility of these markers to guide targeted interventions and improve outcomes.
Article number two. Clinically Actionable Hypertrophic Cardiomyopathy Genes in South Asian Indian Patients. This study aimed to identify the prevalence of clinically actionable gene variants for primary hypertrophic cardiomyopathy in South Asian Indian patients, addressing existing data gaps and disparities in ancestry-specific variant interpretation. The research successfully identified distinct clinically actionable hypertrophic cardiomyopathy gene variants within this specific population, using established guidelines like the ClinGen Hereditary Cardiovascular Disorders Gene Curation Expert Panel. These findings provide crucial genetic insights, enhancing the understanding of hypertrophic cardiomyopathy’s etiology in South Asian Indian individuals. This work is essential for improving accurate genetic diagnosis, facilitating robust risk stratification, and enabling effective cascade screening within affected South Asian Indian families, ultimately minimizing interpretation disparities and improving patient care.
Article number three. Utility of High-Sensitivity Cardiac Troponin-T and N-Terminal Pro-B-Type Natriuretic Peptide to Predict Survival, Quality of Life, and Functional Status Changes After Transcatheter Aortic Valve Implantation. This prospective observational cohort study, involving 173 patients, evaluated the prognostic utility of pre-transcatheter aortic valve implantation N-terminal pro-B-type natriuretic peptide and high-sensitivity cardiac troponin T levels. The study discovered that elevated pre-procedural levels of both N-terminal pro-B-type natriuretic peptide and high-sensitivity cardiac troponin T were significant predictors of poorer survival, reduced quality of life, and diminished functional status changes after transcatheter aortic valve implantation. These findings demonstrate that these cardiac biomarkers offer substantial prognostic value beyond current clinical assessments. Consequently, these biomarkers can be incorporated into aortic valve guidelines to enhance risk stratification and guide more informed patient selection for transcatheter aortic valve implantation.
Article number four. Nonsteroidal Versus Steroidal Mineralocorticoid Receptor Antagonists in Heart Failure: Real-World Evidence From a Multicenter Cohort Study. This retrospective, propensity score-matched cohort study utilized the TriNetX database to provide real-world evidence comparing nonsteroidal and steroidal mineralocorticoid receptor antagonists in heart failure patients. The study enrolled adult patients diagnosed with heart failure who initiated either type of mineralocorticoid receptor antagonist between January 2021 and February 2025. The research demonstrated that nonsteroidal mineralocorticoid receptor antagonists, exemplified by finerenone, offer comparable or superior clinical benefits in reducing mortality and hospitalization rates in heart failure patients. This evidence expands therapeutic options for heart failure management, supporting the selection of mineralocorticoid receptor antagonists to improve patient outcomes in a real-world setting.
Article number five. Rivaroxaban in Peripheral Artery Disease After Revascularization: Worst Events and Net Outcomes in VOYAGER PAD. This analysis of the VOYAGER P.A.D. trial data evaluated the efficacy and safety of rivaroxaban 2.5 milligrams twice daily in patients with peripheral artery disease after revascularization, specifically focusing on “worst events” and net clinical outcomes. The study affirmed rivaroxaban’s benefit in reducing major thrombotic vascular events, building upon the initial finding of a reduced first event in a composite endpoint. It further clarified rivaroxaban’s impact on a spectrum of adverse events, demonstrating an improved overall patient safety and efficacy profile. This comprehensive assessment solidifies rivaroxaban’s role as a vital adjunct to antiplatelet therapy, substantially improving long-term outcomes and reducing re-interventions for peripheral artery disease patients post-revascularization.
Thank you for listening. Don’t forget to subscribe.
Keywords
genetic diagnosis, mineralocorticoid receptor antagonists, hospitalization, N-terminal pro-B-type natriuretic peptide, hypertrophic cardiomyopathy, ischemic stroke, South Asian Indian, Black adults, rivaroxaban, atrial fibrillation, heart failure, ClinGen, genetic variants, thrombotic events, mortality, antiplatelet therapy, high-sensitivity cardiac troponin T, quality of life, revascularization, peripheral artery disease, P-wave indices, atrial cardiomyopathy, finerenone, transcatheter aortic valve implantation.
About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • FollowThe post Nonsteroidal MRAs Improve Heart Failure Outcomes. 10/24/25 first appeared on Cardiology Today.
In God we trust